Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Capital Expenditures (2022 - 2024)

Atara Biotherapeutics (ATRA) has disclosed Capital Expenditures for 3 consecutive years, with $90000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Capital Expenditures fell 19.64% year-over-year to $90000.0, compared with a TTM value of $90000.0 through Sep 2025, down 66.42%, and an annual FY2024 reading of $246000.0, up 86.36% over the prior year.
  • Capital Expenditures was $90000.0 for Q4 2024 at Atara Biotherapeutics, down from $156000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $2.6 million in Q1 2022 and bottomed at -$88000.0 in Q3 2023.
  • Average Capital Expenditures over 3 years is $457100.0, with a median of $122000.0 recorded in 2022.
  • The sharpest move saw Capital Expenditures crashed 166.67% in 2023, then surged 281.4% in 2024.
  • Year by year, Capital Expenditures stood at $37000.0 in 2022, then surged by 202.7% to $112000.0 in 2023, then dropped by 19.64% to $90000.0 in 2024.
  • Business Quant data shows Capital Expenditures for ATRA at $90000.0 in Q4 2024, $156000.0 in Q2 2024, and $112000.0 in Q4 2023.